Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.
Natural killer (NK) cells play a critical role in the body's immune system. Their unique ability to identify and destroy abnormal cells, while leaving healthy cells unharmed, make them a promising treatment option for various cancers and infectious diseases. NK and CAR-NK cells represent an attractive alternate modality with the potential to address shortcomings experienced by T cell and CAR-T-based therapies. NK cell therapies also offer impressive feasibility as an off-the-shelf product, an enhanced safety profile with respect to cytokine release syndrome, neurotoxicity, and graft-versus-host disease, and renewed promise where T cells have fallen short in the solid tumor setting.
As a dedicated cell and gene therapy CDMO, OmniaBio is at the forefront of manufacturing innovation, providing robust technology platforms to propel the industry’s advancement. In the upcoming webinar, we will explore the challenges and opportunities of NK cell therapy development, complemented by a captivating case study highlighting our NK cell therapy platform. The case study will provide valuable insights supported by relevant data for NK cell expansion, NK cell transduction efficiency optimization enabling genetic customization, scale-up to clinically relevant quantities, and key NK analytics and functional assays.